Gonorrhea is most commonly tested with a urine sample or a swab, both of which get sent to a lab for a highly accurate molecular test. The standard test, called a nucleic acid amplification test (NAAT), has greater than 95% sensitivity and specificity, meaning it catches nearly all infections and rarely gives a wrong result. The process is quick, usually painless, and results typically come back within a few days.
The Standard Lab Test
The gold standard for gonorrhea detection is the NAAT, which works by identifying tiny amounts of the bacteria’s genetic material in your sample. This is the same type of test used for chlamydia, and most clinics test for both infections from a single sample. You’ll either provide a urine sample or have a swab collected, depending on the site being tested and your anatomy.
For a urine test, you’ll need to collect the very first part of your urine stream into a sterile cup. To get an accurate result, you should avoid urinating for at least two hours before the test. For swab-based tests, a clinician (or you, in many clinics) uses a small swab or brush to gather fluid and cells from the genital area, such as the vagina, cervix, or urethra. If you’re having a vaginal or cervical swab, avoid using vaginal douches or creams for a day beforehand.
When to Get Tested After Exposure
Gonorrhea won’t show up on a test the day after exposure. The bacteria need time to multiply enough for a test to detect them. Most infections are detectable after one week. Waiting two weeks catches nearly all cases. If you test too early, you could get a negative result despite being infected, so timing matters.
If you’ve been treated for gonorrhea, the CDC recommends retesting three months after treatment to make sure you haven’t been reinfected.
Throat and Rectal Testing
Gonorrhea doesn’t only infect the genitals. It can also establish itself in the throat and rectum, often without any symptoms at all. A standard urine test will completely miss infections at these sites. If you’ve had oral or anal sex, you may need separate swabs from the throat and rectum in addition to a genital sample.
For men who have sex with men, the CDC recommends testing at all sites of contact (urethra, rectum, and throat) at least once a year, regardless of condom use. For women, pharyngeal and rectal screening is considered on a case-by-case basis depending on sexual behaviors and exposure. The key point: if you only test your urine, you could have an active gonorrhea infection in your throat or rectum and never know it.
Rapid Tests That Give Same-Day Results
A newer option is a rapid molecular test that delivers results in about 30 minutes, allowing you to get tested and treated in a single clinic visit. One FDA-cleared rapid test works with vaginal swabs or male urine samples and has sensitivity and specificity above 90%. In clinical trials, it detected 100% of gonorrhea cases from vaginal swabs in both symptomatic and asymptomatic patients, and caught about 98% of cases from male urine samples in symptomatic men.
These rapid tests aren’t available everywhere yet, but they’re increasingly showing up in urgent care clinics and sexual health centers. They’re especially useful when someone is unlikely to return for a follow-up visit.
At-Home Test Kits
At-home gonorrhea testing is available, though with some caveats. The FDA has approved a combined chlamydia, gonorrhea, and trichomoniasis home collection kit for women. With these kits, you collect your own sample at home and mail it to a lab, where the same NAAT technology used in clinics processes it. Results typically come back within a few days.
The lab testing itself is just as accurate as what happens in a clinic. The open question is whether self-collected samples are as reliable as those collected by a healthcare professional. The FDA originally approved these lab tests using clinician-collected samples and is still evaluating whether home collection performs equally well. That said, self-collected vaginal swabs have performed very well in clinical studies, and many clinics already have patients self-collect vaginal swabs on-site.
Older Diagnostic Methods
Before molecular testing became widespread, a microscope-based technique called a Gram stain was the primary rapid diagnostic tool. A clinician examines a sample of discharge under a microscope, looking for the distinctive paired, round bacteria inside white blood cells. This method is still useful for men with visible urethral discharge, where it’s over 95% sensitive and over 99% specific. But it performs poorly for cervical, throat, and rectal infections and isn’t reliable for people without symptoms. In practice, it’s been largely replaced by NAATs for routine testing.
False Positives and Confirmatory Testing
While NAATs are highly accurate, their specificity is over 99% rather than a perfect 100%. In populations where gonorrhea is uncommon, even a small false-positive rate means some positive results won’t actually represent real infections. The CDC recommends that if a false positive would cause significant personal, medical, or psychological harm, a confirmatory test using a different method should be considered. In most clinical situations, though, a positive NAAT is treated as a real infection and antibiotics are started right away.
Who Should Be Screened Routinely
Gonorrhea often causes no symptoms, particularly in women, which is why routine screening matters even when you feel fine. The CDC recommends annual screening for all sexually active women under 25, and for women 25 and older who have risk factors like a new partner, multiple partners, a partner with an STI, inconsistent condom use, or a previous STI. The same recommendations apply to transgender men and gender-diverse people with a cervix.
For men who have sex with men, the recommendation is annual screening at minimum, with testing every three to six months for those at higher risk. People living with HIV should be screened at their first evaluation and at least annually after that. Pregnant women under 25, or those with risk factors, should be screened during pregnancy and again in the third trimester.
For heterosexual men at low risk, there isn’t strong enough evidence to recommend routine screening. Testing in this group is typically driven by symptoms or known exposure to an infected partner.